Surmodics (SRDX) Competitors

Surmodics (NASDAQ:SRDX) and Integra LifeSciences (NASDAQ:IART) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk, community ranking and media sentiment.

Which has more risk and volatility, SRDX or IART?

Surmodics has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Which has better valuation & earnings, SRDX or IART?

Integra LifeSciences has higher revenue and earnings than Surmodics. Integra LifeSciences is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surmodics	$126.08M	4.18	-$11.54M	-$0.81	-45.53
Integra LifeSciences	$1.54B	1.21	$67.74M	-$0.09	-267.75

Does the MarketBeat Community favor SRDX or IART?

Integra LifeSciences received 100 more outperform votes than Surmodics when rated by MarketBeat users. However, 62.64% of users gave Surmodics an outperform vote while only 56.83% of users gave Integra LifeSciences an outperform vote.

Company	Underperform	Outperform
Surmodics	Outperform Votes 337 62.64%	Underperform Votes 201 37.36%
Integra LifeSciences	Outperform Votes 437 56.83%	Underperform Votes 332 43.17%

Does the media prefer SRDX or IART?

In the previous week, Integra LifeSciences had 2 more articles in the media than Surmodics. MarketBeat recorded 5 mentions for Integra LifeSciences and 3 mentions for Surmodics. Integra LifeSciences' average media sentiment score of 0.17 beat Surmodics' score of -0.10 indicating that Integra LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surmodics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integra LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend SRDX or IART?

Surmodics presently has a consensus target price of $50.00, indicating a potential upside of 35.57%. Integra LifeSciences has a consensus target price of $23.00, indicating a potential downside of 4.56%. Given Surmodics' stronger consensus rating and higher probable upside, research analysts plainly believe Surmodics is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surmodics	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Integra LifeSciences	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Is SRDX or IART more profitable?

Integra LifeSciences has a net margin of -0.42% compared to Surmodics' net margin of -9.15%. Integra LifeSciences' return on equity of 12.35% beat Surmodics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surmodics	-9.15%	-3.79%	-2.55%
Integra LifeSciences	-0.42%	12.35%	4.82%

Do insiders & institutionals have more ownership in SRDX or IART?

96.6% of Surmodics shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 8.9% of Surmodics shares are owned by insiders. Comparatively, 3.1% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Integra LifeSciences beats Surmodics on 10 of the 18 factors compared between the two stocks.